US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alto Neuroscience

2.26

+0.01000.44%

Post-market: 2.25-0.0100-0.44%16:58 EDT

Volume:148.83K

Turnover:332.58K

Market Cap:61.18M

PE:-0.91

High:2.27

Open:2.19

Low:2.15

Close:2.25

Loading ...

Overview Company News Filings

Metagenomi Leads The Charge With These 3 Penny Stocks

Simply Wall St.

Alto Neuroscience initiated with a Buy at H.C. Wainwright

Alto Neuroscience Initiated at Buy by HC Wainwright & Co.

Alto Neuroscience, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS

JonesTrading Sticks to Its Buy Rating for Alto Neuroscience, Inc. (ANRO)

Buy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data Readouts

Promising Clinical Trials and Strong Financials Justify Buy Rating for Alto Neuroscience, Inc.

Alto Neuroscience Advances Clinical Trials with Strong Financials

BRIEF-Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights

Alto Neuroscience FY 2024 GAAP EPS $(2.50) Beats $(2.59) Estimate

Alto Neuroscience Inc: Expected to Fund Planned Operations Into 2028

THOMSON REUTERS

Press Release: Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Calendar of U.S. Earnings Expected in the Week Ahead

Calendar of U.S. Earnings Expected in the Week Ahead

Christopher Nixon Cox Named Chairman of High-Trend International Group

THOMSON REUTERS

Press Release: Christopher Nixon Cox Named Chairman of High-Trend International Group

Alto Neuroscience rises 25.0%

Alto Neuroscience to Participate in Upcoming Investor Conferences

BRIEF-Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker

Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ANRO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ANRO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","market":"US","secType":"STK","nameCN":"Alto Neuroscience","latestPrice":2.26,"timestamp":1744920000000,"preClose":2.25,"halted":0,"volume":148826,"hourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.26,"latestTime":"16:58 EDT","volume":2704,"amount":6110,"timestamp":1744923514349},"delay":0,"floatShares":19503522,"shares":27072129,"eps":-2.496992,"marketStatus":"Market Closed","change":0.01,"latestTime":"04-17 16:00:00 EDT","open":2.19,"high":2.27,"low":2.15,"amount":332576.28305519995,"amplitude":0.053333,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.496992,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"listingDate":1706850000000,"exchange":"NYSE","adjPreClose":2.25,"postHourTrading":{"tag":"盘后","latestPrice":2.25,"preClose":2.26,"latestTime":"16:58 EDT","volume":2704,"amount":6110,"timestamp":1744923514349},"volumeRatio":0.49232009004342253,"impliedVol":1.8281,"impliedVolPercentile":0.2055},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ANRO\",,,,,undefined,":{"symbol":"ANRO","floatShares":19503522,"roa":"-32.46%","roe":"-55.19%","lyrEps":-2.496992,"volumeRatio":0.49232009004342253,"shares":27072129,"dividePrice":0,"high":2.27,"amplitude":0.053333,"preClose":2.25,"low":2.15,"week52Low":1.6,"pbRate":"0.40","week52High":17.55,"institutionHeld":0,"latestPrice":2.26,"eps":-2.496992,"divideRate":0,"volume":148826,"delay":0,"ttmEps":-2.496992,"open":2.19,"prevYearClose":4.23,"prevWeekClose":2.13,"prevMonthClose":2.16,"prevQuarterClose":2.16,"fiveDayClose":2.05,"twentyDayClose":2.69,"sixtyDayClose":4.52},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ANRO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526829176","title":"Metagenomi Leads The Charge With These 3 Penny Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2526829176","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526829176?lang=en_us&edition=fundamental","pubTime":"2025-04-09 01:05","pubTimestamp":1744131909,"startTime":"0","endTime":"0","summary":"As U.S. markets navigate the complexities of tariff negotiations and economic uncertainty, investors are keeping a close eye on potential opportunities within various sectors. Penny stocks, often representing smaller or newer companies, continue to pique interest due to their potential for both value and growth—despite being an older term in the investment lexicon. In this article, we explore three penny stocks that stand out for their robust financials and growth prospects, offering...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mgx/metagenomi/news/metagenomi-leads-the-charge-with-these-3-penny-stocks","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4505","BK4021","BK4023","TTI","BK4509","BK4209","BK4007","BABB","BK4526","BK4563","MGX","SB","SEER","TUYA","BK4139","BK4121","BK4179","ANRO"],"gpt_icon":0},{"id":"2525811818","title":"Alto Neuroscience initiated with a Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2525811818","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525811818?lang=en_us&edition=fundamental","pubTime":"2025-04-08 22:15","pubTimestamp":1744121731,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience  with a Buy rating and $10 price target Alto is redefining neuropsychiatric drug development through the application of precision medicine in psychiatry, a “paradigm-shifting approach” that targets biomarker-defined patient populations, the analyst tells investors in a research note. The firm believes the company’s “differentiated” Precision Psychiatry Platform has the potential to optimize patient-treatment matching and outcomes in central nervous system disorders.Discover outperforming stocks and invest smarter with Top Smart Score Stocks.Filter, analyze, and streamline your search for investment opportunities using  Tipranks' Stock Screener.Buy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data Readouts. Promising Clinical Trials and Strong Financials Justify Buy Rating for Alto Neuroscience, Inc.Alto Neuroscience Advances Clinical Trials with Strong Financials","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/alto-neuroscience-initiated-buy-h-141531554.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-initiated-buy-h-141531554.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2525042555","title":"Alto Neuroscience Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2525042555","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525042555?lang=en_us&edition=fundamental","pubTime":"2025-04-07 22:27","pubTimestamp":1744036020,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANRO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2025 10:27 ET (14:27 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2525044424","title":"Alto Neuroscience, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2525044424","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525044424?lang=en_us&edition=fundamental","pubTime":"2025-04-07 22:14","pubTimestamp":1744035285,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250407:nAZN3O5D1P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2521736377","title":"JonesTrading Sticks to Its Buy Rating for Alto Neuroscience, Inc. (ANRO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2521736377","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521736377?lang=en_us&edition=fundamental","pubTime":"2025-03-24 22:35","pubTimestamp":1742826912,"startTime":"0","endTime":"0","summary":"In a report released on March 20, Justin Walsh from JonesTrading reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), with ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-alto-neuroscience-inc-anro?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-alto-neuroscience-inc-anro?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2521735777","title":"Buy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2521735777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521735777?lang=en_us&edition=fundamental","pubTime":"2025-03-24 22:25","pubTimestamp":1742826338,"startTime":"0","endTime":"0","summary":"Analyst Justin Walsh of JonesTrading reiterated a Buy rating on Alto Neuroscience, Inc. (ANRO – Research Report), retaining the price target of $18...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-for-alto-neuroscience-inc-amid-promising-pipeline-and-upcoming-data-readouts?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/buy-rating-reaffirmed-for-alto-neuroscience-inc-amid-promising-pipeline-and-upcoming-data-readouts?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2521540251","title":"Promising Clinical Trials and Strong Financials Justify Buy Rating for Alto Neuroscience, Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2521540251","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521540251?lang=en_us&edition=fundamental","pubTime":"2025-03-22 03:55","pubTimestamp":1742586911,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Ritu Baral has maintained their bullish stance on ANRO stock, giving a Buy rating today. Ritu Baral has given his Buy rating due t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/promising-clinical-trials-and-strong-financials-justify-buy-rating-for-alto-neuroscience-inc?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/promising-clinical-trials-and-strong-financials-justify-buy-rating-for-alto-neuroscience-inc?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO"],"gpt_icon":0},{"id":"2521442774","title":"Alto Neuroscience Advances Clinical Trials with Strong Financials","url":"https://stock-news.laohu8.com/highlight/detail?id=2521442774","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521442774?lang=en_us&edition=fundamental","pubTime":"2025-03-21 12:08","pubTimestamp":1742530086,"startTime":"0","endTime":"0","summary":"Alto Neuroscience, Inc. ( ($ANRO) ) has released its Q4 earnings. Here is a breakdown of the information Alto Neuroscience, Inc. presented to its i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-advances-clinical-trials-with-strong-financials?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/alto-neuroscience-advances-clinical-trials-with-strong-financials?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANRO","BK4007"],"gpt_icon":0},{"id":"2521912424","title":"BRIEF-Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521912424","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521912424?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:56","pubTimestamp":1742504176,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Reports Full-Year 2024 Financial Results And Recent Business HighlightsMarch 20 (Reuters) - Alto Neuroscience Inc ANRO.N:ALTO NEUROSCIENCE REPORTS FULL-YEAR 2024 FINANCIAL RESU","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA4TTC9R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2521049964","title":"Alto Neuroscience FY 2024 GAAP EPS $(2.50) Beats $(2.59) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2521049964","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521049964?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:21","pubTimestamp":1742502082,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(2.50) per share which beat the analyst consensus estimate of $(2.59) by 3.47 percent.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44425506/alto-neuroscience-fy-2024-gaap-eps-2-50-beats-2-59-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Alto Neuroscience FY 2024 GAAP EPS $(2.50) Beats $(2.59) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO"],"gpt_icon":0},{"id":"2521413496","title":"Alto Neuroscience Inc: Expected to Fund Planned Operations Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2521413496","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521413496?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:10","pubTimestamp":1742501400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nTUA4TTC9R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2521499351","title":"Press Release: Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2521499351","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521499351?lang=en_us&edition=fundamental","pubTime":"2025-03-21 04:10","pubTimestamp":1742501400,"startTime":"0","endTime":"0","summary":"-- Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 --. -- Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 --. -- Novel transdermal formulation of ALTO-101 demonstrated greater drug exposure and improved tolerability profile; topline data from Phase 2 trial of ALTO-101 in schizophrenia expected in the second half of 2025 --. -- Company's precision psychiatry approach underpins recently granted patents covering the use of ALTO-100 and ALTO-300 in biomarker defined populations --. -- Strong cash position of approximately $169 million expected to fund planned operations into 2028, and through at least four upcoming clinical study readouts --. Alto Neuroscience, Inc.   a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the ful","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ANRO","ABVC"],"gpt_icon":0},{"id":"2520889517","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520889517","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520889517?lang=en_us&edition=fundamental","pubTime":"2025-03-17 18:00","pubTimestamp":1742205600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANRO","INO","NRXP","LEN.B","AUTL","HYPR","CAL","LVTX","SCPH","SPRY","PL","IMTX","RWAY","CMC","OSS","GLUE","OABI","DRI","BTM","BLTE","KLC","KOPN","RBOT","RANI","CNTX","SGMO","ASO","DMAC","NOA","SAIC","ABSI","LAR","STNE","MSIF","CELC","CBUS","LPRO","LQDA","FIVE","OPTN","AEVA","DERM","FLUX","BCAB","STTK","LXEO","SIG","PHUN"],"gpt_icon":1},{"id":"2519876572","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2519876572","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519876572?lang=en_us&edition=fundamental","pubTime":"2025-03-14 18:00","pubTimestamp":1741946400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Bitcoin Depot Inc.                               4Q       .02   8:05 AM. ·IHS Hldg Ltd.                                    4Q       .01   6:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLYB","HYPR","LQDA","AMPX","FDX","TME","LVTX","MGNX","LAR","MBRX","NRXP","DRI","TYRA","MRC","ERAS","IFRX","CAPR","LE","IDN","GOGO","ABSI","DTIL","NKTX","GANX","OSS","STNE","AEVA","INKT","PL","AUTL","ACN","JILL","INSE","LXEO","DTI","KOPN","RANI","PRSO","HROW","SPRY","ANRO","CNTX","CAL","HTHT","GIS","LPRO","FDS"],"gpt_icon":1},{"id":"2519831370","title":"Christopher Nixon Cox Named Chairman of High-Trend International Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2519831370","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519831370?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:00","pubTimestamp":1741870814,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nTUA5GX1ML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4021","ANRO","BK4007","HTCO"],"gpt_icon":0},{"id":"2519315278","title":"Press Release: Christopher Nixon Cox Named Chairman of High-Trend International Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2519315278","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519315278?lang=en_us&edition=fundamental","pubTime":"2025-03-13 21:00","pubTimestamp":1741870800,"startTime":"0","endTime":"0","summary":"SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group  , an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid rapid expansion.Shixuan He, CEO of the company commented that,\"Mr. Cox's appointment marks","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HTCO","BK4021","ANRO","BK4007"],"gpt_icon":0},{"id":"2516637169","title":"Alto Neuroscience rises 25.0%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637169","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516637169?lang=en_us&edition=fundamental","pubTime":"2025-03-03 22:51","pubTimestamp":1741013482,"startTime":"0","endTime":"0","summary":"Alto Neuroscience (ANRO) is up 25.0%, or 70c to $3.50. Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-rises-25-0?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/alto-neuroscience-rises-25-0?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2514706099","title":"Alto Neuroscience to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2514706099","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514706099?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:03","pubTimestamp":1740488580,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., February 25, 2025----Alto Neuroscience, Inc.  , a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in March:. TD Cowen 45th Annual Health Care Conference, March 3-5th 2025:. Presentation Date/Time: Tuesday, March 4, 2025, at 9:50 am ET. Leerink’s Global Healthcare Conference 2025, March 10-12th 2025:. Presentation Date/Time: Wednesday, March 12, 2025, at 8:00 am ET. Stifel 2025 Virtual CNS Forum, March 18-19th 2025:. Presentation Date/Time: Tuesday, March 18, 2025, at 1:00 pm ET. Available presentations will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto’s website and a replay will be available following the presentation.Alto routinely uses its investor relations website to post presentations to inves","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/alto-neuroscience-participate-upcoming-investor-130300254.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ANRO"],"gpt_icon":0},{"id":"2512856064","title":"BRIEF-Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2512856064","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512856064?lang=en_us&edition=fundamental","pubTime":"2025-02-19 23:08","pubTimestamp":1739977692,"startTime":"0","endTime":"0","summary":"BRIEF-Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 As A Treatment For Patients With Major Depressive Disorder Characterized By An Electroencephalogram BiomarkerFeb 19 (Reuters) - ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA2MLZKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ANRO"],"gpt_icon":1},{"id":"2512270101","title":"Alto Neuroscience Announces U.S. Patent Granted Covering Alto-300 as a Treatment for Patients With Major Depressive Disorder Characterized by an Electroencephalogram Biomarker","url":"https://stock-news.laohu8.com/highlight/detail?id=2512270101","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512270101?lang=en_us&edition=fundamental","pubTime":"2025-02-19 21:03","pubTimestamp":1739970180,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250219:nTUA2MLZKP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ANRO"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ANRO\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ANRO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ANRO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ANRO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ANRO","date":"2025-04-17","current":-0.991556,"percent":0.964664,"low":-16.978804,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"high":-0.793245,"avg":-5.903458,"sd":4.046455,"marketCap":60912290},"quantilePoints":[{"date":"2024-02-09","current":-15.481605,"twenty":-16.048587,"median":-15.481605,"eighty":-13.872658,"marketCap":506867732},{"date":"2024-02-16","current":-12.96931,"twenty":-15.548491,"median":-13.234406,"eighty":-11.571235,"marketCap":424615224},{"date":"2024-02-23","current":-10.603839,"twenty":-15.481605,"median":-12.585941,"eighty":-11.026361,"marketCap":347169680},{"date":"2024-03-01","current":-12.56147,"twenty":-14.292343,"median":-12.488059,"eighty":-11.135662,"marketCap":411262544},{"date":"2024-03-08","current":-11.631595,"twenty":-13.230328,"median":-12.361629,"eighty":-11.293904,"marketCap":380818433},{"date":"2024-03-15","current":-12.153631,"twenty":-13.001937,"median":-12.137317,"eighty":-11.306955,"marketCap":397909864},{"date":"2024-03-22","current":-11.14409,"twenty":-12.949734,"median":-12.108768,"eighty":-11.306955,"marketCap":404586204},{"date":"2024-03-28","current":-12.415912,"twenty":-12.956259,"median":-12.145474,"eighty":-11.437463,"marketCap":450759680},{"date":"2024-04-05","current":-10.418119,"twenty":-12.920369,"median":-11.868143,"eighty":-11.162905,"marketCap":378229815},{"date":"2024-04-12","current":-10.440317,"twenty":-12.863272,"median":-11.793418,"eighty":-10.823597,"marketCap":379035702},{"date":"2024-04-19","current":-9.988964,"twenty":-12.713187,"median":-11.631595,"eighty":-10.532067,"marketCap":362649325},{"date":"2024-04-26","current":-10.455115,"twenty":-12.538631,"median":-11.566341,"eighty":-10.461035,"marketCap":379572960},{"date":"2024-05-03","current":-10.654895,"twenty":-12.497847,"median":-11.513206,"eighty":-10.478793,"marketCap":386825947},{"date":"2024-05-10","current":-10.802879,"twenty":-12.4592,"median":-11.360121,"eighty":-10.478793,"marketCap":392198529},{"date":"2024-05-17","current":-8.114957,"twenty":-12.377436,"median":-11.191128,"eighty":-10.431438,"marketCap":344382544},{"date":"2024-05-24","current":-7.443985,"twenty":-12.295701,"median":-11.079356,"eighty":-10.270134,"marketCap":315907856},{"date":"2024-05-31","current":-7.59948,"twenty":-12.254775,"median":-10.943138,"eighty":-9.999323,"marketCap":322506720},{"date":"2024-06-07","current":-7.453823,"twenty":-12.218885,"median":-10.773282,"eighty":-9.088414,"marketCap":316325341},{"date":"2024-06-14","current":-7.612146,"twenty":-12.153631,"median":-10.654895,"eighty":-8.114957,"marketCap":323044231},{"date":"2024-06-21","current":-6.997854,"twenty":-12.14058,"median":-10.580902,"eighty":-7.890353,"marketCap":296974938},{"date":"2024-06-28","current":-6.731872,"twenty":-12.125897,"median":-10.558705,"eighty":-7.854905,"marketCap":285687202},{"date":"2024-07-05","current":-7.35883,"twenty":-12.080219,"median":-10.514309,"eighty":-7.738804,"marketCap":312294007},{"date":"2024-07-12","current":-8.486086,"twenty":-11.912764,"median":-10.492111,"eighty":-7.738804,"marketCap":360132504},{"date":"2024-07-15","current":-8.840728,"twenty":-11.90384,"median":-10.492111,"eighty":-7.738804,"marketCap":375182817},{"date":"2024-08-02","current":-6.212575,"twenty":-11.894916,"median":-10.481012,"eighty":-7.674208,"marketCap":263649243},{"date":"2024-08-09","current":-5.762939,"twenty":-11.86488,"median":-10.440317,"eighty":-7.584281,"marketCap":244567596},{"date":"2024-08-16","current":-5.077305,"twenty":-11.842621,"median":-10.421819,"eighty":-7.439715,"marketCap":252875166},{"date":"2024-08-23","current":-5.770157,"twenty":-11.798049,"median":-10.270134,"eighty":-7.320833,"marketCap":287382652},{"date":"2024-08-30","current":-6.766131,"twenty":-11.747422,"median":-10.066655,"eighty":-7.023186,"marketCap":336987162},{"date":"2024-09-06","current":-6.885215,"twenty":-11.696849,"median":-9.985264,"eighty":-6.997854,"marketCap":342918136},{"date":"2024-09-13","current":-7.036776,"twenty":-11.629964,"median":-9.589405,"eighty":-7.005638,"marketCap":350466649},{"date":"2024-09-20","current":-7.269531,"twenty":-11.615282,"median":-8.800669,"eighty":-7.041657,"marketCap":362059007},{"date":"2024-09-27","current":-6.495486,"twenty":-11.576129,"median":-8.327763,"eighty":-6.997854,"marketCap":323507676},{"date":"2024-10-04","current":-5.51575,"twenty":-11.542663,"median":-8.073812,"eighty":-6.792939,"marketCap":274711934},{"date":"2024-10-11","current":-6.392641,"twenty":-11.505807,"median":-7.947789,"eighty":-6.506312,"marketCap":318385471},{"date":"2024-10-18","current":-7.724215,"twenty":-11.453451,"median":-7.863613,"eighty":-6.586066,"marketCap":384704544},{"date":"2024-10-25","current":-2.23553,"twenty":-11.361501,"median":-7.821648,"eighty":-6.506312,"marketCap":111340558},{"date":"2024-10-31","current":-2.181401,"twenty":-11.357822,"median":-7.776801,"eighty":-6.403467,"marketCap":108644661},{"date":"2024-11-08","current":-2.083968,"twenty":-11.223755,"median":-7.738804,"eighty":-6.212575,"marketCap":103792046},{"date":"2024-11-15","current":-2.159604,"twenty":-11.191128,"median":-7.724215,"eighty":-6.11117,"marketCap":124062772},{"date":"2024-11-22","current":-1.92017,"twenty":-11.14409,"median":-7.634377,"eighty":-5.98126,"marketCap":110307987},{"date":"2024-11-29","current":-2.070403,"twenty":-11.113816,"median":-7.615312,"eighty":-5.768005,"marketCap":118938440},{"date":"2024-12-06","current":-1.830969,"twenty":-11.06322,"median":-7.574148,"eighty":-5.648645,"marketCap":105183655},{"date":"2024-12-13","current":-1.798105,"twenty":-11.000259,"median":-7.504253,"eighty":-5.44863,"marketCap":103295743},{"date":"2024-12-20","current":-1.746462,"twenty":-10.916697,"median":-7.443985,"eighty":-5.07514,"marketCap":100329024},{"date":"2024-12-27","current":-2.075098,"twenty":-10.841355,"median":-7.436869,"eighty":-2.363274,"marketCap":119208142},{"date":"2025-01-03","current":-2.056319,"twenty":-10.79104,"median":-7.390494,"eighty":-2.255016,"marketCap":118129335},{"date":"2025-01-10","current":-2.070403,"twenty":-10.767363,"median":-7.35883,"eighty":-2.165554,"marketCap":118938440},{"date":"2025-01-17","current":-2.079793,"twenty":-10.725927,"median":-7.312287,"eighty":-2.141345,"marketCap":119477844},{"date":"2025-01-24","current":-2.272279,"twenty":-10.654895,"median":-7.277651,"eighty":-2.138097,"marketCap":130535613},{"date":"2025-01-31","current":-2.093877,"twenty":-10.603839,"median":-7.253293,"eighty":-2.122046,"marketCap":120286949},{"date":"2025-02-07","current":-1.854443,"twenty":-10.580902,"median":-7.17813,"eighty":-2.093877,"marketCap":106532163},{"date":"2025-02-14","current":-1.530502,"twenty":-10.558705,"median":-7.145034,"eighty":-2.075098,"marketCap":87922747},{"date":"2025-02-21","current":-1.464775,"twenty":-10.529107,"median":-7.061183,"eighty":-2.070403,"marketCap":84146924},{"date":"2025-02-28","current":-1.305152,"twenty":-10.515789,"median":-6.997854,"eighty":-2.041295,"marketCap":74977067},{"date":"2025-03-07","current":-1.854443,"twenty":-10.50839,"median":-6.933931,"eighty":-2.023455,"marketCap":106532163},{"date":"2025-03-14","current":-1.483554,"twenty":-10.495071,"median":-6.768,"eighty":-2.01289,"marketCap":85225730},{"date":"2025-03-21","current":-1.180996,"twenty":-10.492111,"median":-6.549615,"eighty":-1.993408,"marketCap":72549751},{"date":"2025-03-28","current":-1.062067,"twenty":-10.474353,"median":-6.422411,"eighty":-1.971812,"marketCap":65243830},{"date":"2025-04-04","current":-0.81528,"twenty":-10.458075,"median":-6.392641,"eighty":-1.92017,"marketCap":50083438},{"date":"2025-04-11","current":-0.903418,"twenty":-10.443277,"median":-6.253891,"eighty":-1.873222,"marketCap":55497864},{"date":"2025-04-17","current":-0.991556,"twenty":-10.440317,"median":-6.19297,"eighty":-1.833785,"marketCap":60912290}],"updateTime":1745066970120}}}